The presentation time can be found on the Company's website. Please check www.ionispharma.com for the latest information.
A live webcast of the presentation will be available on the Investors & Media section of the Ionis website. The replay will be available within 48 hours and will be archived for a limited time.
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs – such as children and adults with spinal muscular atrophy (SMA). We created SPINRAZA® (nusinersen)* and are proud to have brought new hope to the SMA community by developing the first and only approved treatment for this disease.
Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 drugs with the potential to treat patients with cardiovascular disease, rare diseases, neurological diseases, infectious diseases and cancer. We created TEGSEDI™ (inotersen) the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy of hereditary transthyretin (TTR) amyloidosis (ATTR) in adult patients that our affiliate
To learn more about Ionis follow us on twitter @ionispharma or visit http://ir.ionispharma.com/.
*Spinraza is marketed by Biogen.
IONIS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Ionis' business, and the therapeutic and commercial potential of SPINRAZA®, TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen) and Ionis' technologies and products in development, including the business of
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to
View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-jefferies-2018-london-healthcare-conference-300748669.html
Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D.; Vice President, Investor Relations; 760-603-2741 OR Ionis Pharmaceuticals Media Contact: Roslyn Patterson; Vice President, Corporate Communications; 760-603-2681